Revenue
No reported data
ACTUATE THERAPEUTICS, INC. (ACTU)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Research & development | $10.3M | $18.7M | $21.7M |
| Operating expenses | $22.5M | $25.2M | $25.0M |
| Operating income | −$22.5M | −$25.2M | −$25.0M |
| Net income | −$22.2M | −$27.3M | −$24.7M |
| Basic EPSper diluted share | -$1.06 | -$3.26 | -$17.24 |
| Diluted EPSper diluted share | -$1.06 | -$3.26 | -$17.24 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 5, 2026Form 4 | THOMSON TODD S +1Director,TenPercentOwner | SellCommon Stock · indirect | 280.0K | $5.80 | $1.62M | 904.8K |
| Jun 27, 2025Form 4 | Bios Equity COF, LP +3Director,TenPercentOwner | BuyCommon Stock · indirect | 71.4K | $7.00 | $500.0K | 196.4K |
| Jun 27, 2025Form 4 | Bios Equity COF, LP +3Director,TenPercentOwner | BuyWarrant (Right to Buy) · derivative · indirect | 71.4K | $0.00 | $0.00 | 71.4K |
| Jun 27, 2025Form 4 | BIOS Fund II, LP +9Director,TenPercentOwner | BuyCommon Stock · indirect | 71.4K | $7.00 | $500.0K | 196.4K |
| Jun 27, 2025Form 4 | BIOS Fund II, LP +9Director,TenPercentOwner | BuyWarrant (Right to Buy) · derivative · indirect | 71.4K | $0.00 | $0.00 | 71.4K |